Skip to main content
. 2024 Apr 26;9(5):103008. doi: 10.1016/j.esmoop.2024.103008

Figure 3.

Figure 3

(A) Overall survival (OS) and (B) relative survival (RS) from the date of diagnosisofpatients diagnosed with triple-negative breast cancer (TNBC) and high-risk hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer. CI, confidence interval.